News | Proton Therapy | October 28, 2016

IBA Reaches 50,000 Patients Treated with Proton Therapy Systems

With the number of treated patients growing by over 20 percent year by year, patient access will double by 2020, according to the company

IBA, proton therapy, 50,000 patients treated, milestone

October 27, 2016 — IBA announced in September that 50,000 patients have been treated by clinical partners using IBA’s proton therapy technology.

Today, on average, one new patient is treated every hour on IBA systems around the globe, according to Yves Jongen, chief research officer and founder of IBA. The company’s mission, Jongen said, is to make proton therapy available to an estimated 20 percent of radiation patients that could benefit from this type of treatment.

More and more clinical opinion leaders are working on collecting and producing evidence confirming the added value of proton therapy. This addresses not only comparative clinical outcome, but also economic effectiveness of the total treatment. Proton therapy is offering new hope for patients with specific brain, eye, lung and head and neck cancers, due to their very sensitive locations in the body, where it is imperative to preserve surrounding healthy tissue. Most importantly, proton therapy has emerged as a preferred treatment option for pediatric cases, according to IBA, where the damage done to the still growing tissues and organs of children is often irreversible.

This is the reason why IBA said it is investing between 12-15 percent of its revenue in research and development (R&D) — currently the largest share in the sector. One of the outcomes of IBA’s R&D was the ProteusOne proton therapy solution. This is the most compact proton therapy system ever designed, according to the company, which is easier to implement, operate and finance.

IBA said the future of proton therapy is even more encouraging in the light of the advent of adaptive proton therapy (adaPT), widely considered as the next breakthrough in the field. Adaptive workflows, as modular proton therapy processes, add yet another layer of accuracy in what many consider the most precise and least intrusive cancer treatment method. IBA recently created an international online Community platform, leadingthepath.org, to enable experts in the field from all over the world to exchange experiences, discuss best practices and enhance knowledge, to improve the next generation of proton therapy treatment.

For more information: www.iba-worldwide.com

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
Elekta Unity MR Linac system
News | Radiation Oncology | January 30, 2020
January 30, 2020 — Elekta announced that it signed a contract wit
IBA ProteusOne proton therapy system
News | Proton Therapy | January 29, 2020
January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down